Comparison of drug and cell-based delivery: Engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models

Stem Cells Translational Medicine

Volumn 2, Issue 5, 2013, Pages 362-375

  Liu, Linda N ^a   Wang, Gang ^a   Hendricks, Kyle ^a   Lee, Keunmyoung ^a   Bohnlein, Ernst ^b   Junker, Uwe ^b   Mosca, Joseph D ^a  

^a OSIRIS THERAPEUTICS INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adult stem cells; Arthritis; Chondrogenesis; Gene therapy; Immunodeficient mouse; Mesenchymal stem cells; SCID mice; sTNFR

Indexed keywords

ALGINIC ACID; COLLAGEN TYPE 2; DEXAMETHASONE; ENHANCED GREEN FLUORESCENT PROTEIN; ETANERCEPT; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; IMMUNOGLOBULIN G1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; LIPOPOLYSACCHARIDE; NITRIC OXIDE; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; NORMAL HUMAN; NORTHERN BLOTTING; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; STEM CELL GENE THERAPY;

EID: 84877676492     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0135     Document Type: Article

References (74)

1. Schaible HG, Segond von Banchet G, Boettger MK et al. The role of proinflammary cytokines in the generation and maintenance of joint pain. Ann NY Acad Sci 2010;1193:60-69.
2. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
3. Black RA, Rauch CT, Kozlosky CJ et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997; 385:729-733.
4. Moss ML, Catherine Jin SL, Milla ME et al. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α Nature 1997;385:733-737.
5. Sivalingam SP, Thumboo J, Vasoo S et al. In vivo pro- and anti-inflammatory cytokines in normal and patients with rheumatoid arthritis. Ann Acad Med Singapore 2007;36:96-99.
6. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998; 20:133-147.
7. Pedersen SJ, Hetland ML, Sorensen IJ et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol 2010;29:1301-1309.
8. Williams RO, Feldmann M, Maini RN. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-9788.
9. Piguet PF, Grau GE, Vesin C et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-514.
10. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO J 1991;10:4025-4035.
11. Kawane K, Tanaka H, Kitahara Y et al. Cytokine-dependent but acquired immunityindependent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci USA 2010;107:19432-19437.
12. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147.
13. Gibofsky A, Palmer WR, Keystone EC et al. Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: Safety and Etanerceptα utilization analyses from the RADIUS 1 and RADIUS 2 registries. J Rheumatol 2011;38:21-28.
14. Kull FC Jr., Jacobs S, Cuatrecasas P. Cellular receptor for 125I-labeled tumor necrosis factor: Specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci USA 1985;82:5756-5760.
15. Gattorno M, Picco P, Buoncompagni A et al. Serum p55 and p75 tumor necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996; 55:243-247.
16. Mazza J, Rossi A, Weinberg JM. Innovative uses of tumor necrosis factor alpha inhibitors. Dermatol Clin 2010;28:559-575.
17. Wallis RS. Tumor necrosis factor antagonists: Structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-611.
18. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-426.
19. Pearl-Yafe M, Mizrahi K, Stein J et al. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. STEM CELLS 2010;28: 1270-1280.
20. Samira S, Ferrand C, Peled A et al. Tumor necrosis factor promotes human T-cell development in non-obese diabetic/severe combined immunodeficient mice. STEM CELLS 2004; 22:1085-1100.
21. Haque A, Stanley AC, Amante FH et al. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4α T cell responses enhances antiparasitic immunity. J Immunol 2010;184:2583-2592.
22. Kayamuro H, Abe Y, Yoshioka Y et al. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 2009;30:5869-5876.
23. Calzascia T, Pellegrini M, Hall H et al. TNFalpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007;117: 3833-3845.
24. Pasparakis M, Alexopoulou L, Episkopou V et al. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996;184:1397-1411.
25. Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. J Am Soc Nephrol 2004;15:2728-2734.
26. Kelley G. 1987-2002: 15 years: EPO saga to augur regulatory change BioPharm International 2002;15:44.
27. Gaspar R, Duncan R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 2009;61:1220-1231.
28. Lee K, Majumdar MK, Buyaner D et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001;3:857-866.
29. Klyushnenkova E, Mosca JD, Zernetkina V et al. T cell responses to allogeneic human mesenchymal stem cells: Immunogenicity, tolerance, and suppression. J Biomed Sci 2005;12:47-57.
30. Djouad F, Bouffi C, Ghannam S et al. Mesenchymal stem cells: Innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009;5:392-399.
31. Mosca JD, Hendricks JK, Buyaner D et al. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000;379:S71- S90.
32. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
33. Majumdar MK, Thiede MA, Mosca JD et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells and stromal cells. J Cell Physiol 1998; 176:57-66.
34. Forestell SP, Dando JS, Chen J et al. Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer. Gene Ther 1997;4: 600-610.
35. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992;13:81-88.
36. Jaiswal RK, Jaiswal N, Bruder SP et al. Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 2000;275:9645-9652.
37. Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: Differentiation-dependent gene expression of matrix components. Exp Cell Res 2001;268:189-200.
38. Spirito S, Goldberg RL. The ability of nitric oxide (NO) inhibitors to reverse an interleukin-1 (IL-1) induced depression of proteoglycan synthesis is age dependent. Inflamm Res 1997; 46:S131-S132.
39. Bruder SP, Kurth AA, Shea M et al. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998;16:155-162.
40. Stadler J, Stefanovic-Racic M, Billiar TR et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915-3920.
41. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 2003;10: 228-241.
42. Shultz LD, Schweitzer PA, Christianson SW et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-191.
43. Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 1987;45:348-355.
44. Sekut L, Menius JA, Brackeen MF et al. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J Lab Clin Med 1994;124:813-820.
45. Wang Y, Kristan J, Hao L et al. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J Immunol 2000; 164:4340-4347.
46. Mosley B, Beckmann BP, March CJ et al. The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms. Cell 1989;59:335-348.
47. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173: 5343-5348.
48. Hussey RE, Richardson NE, Kowalski M et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988;331:78-81.
49. Traunecker A, Luke W, Karjalainen K. Soluble CD4 molecules neutralize human immunodeficiency virus type I. Nature 1988;331:84-86.
50. Ogawa T, Takayama K, Takakura N et al. Anti-tumor angiogenesis therapy using soluble receptors: Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endo thelial growth factor receptor. Cancer Gene Ther 2002;9:633-640.
51. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell 2009;4:206-216.
52. Myers TJ, Granero-Molto F, Longobardi L et al. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther 2010;10:1663-1679.
53. Hong HS, Kim YH, Son Y. Perspectives on mesenchymal stem cells: Tissue repair, immune modulation, and tumor homing. Arch Pharm Res 2012;35:201-211.
54. Wang G, Liu LN, Lee K et al. Comparison of drug and cell-based delivery: Engineering adult mesenchymal stem cells to deliver human erythropoietin. Gene Ther Mol Biol 2009; 13:321-330.
55. Liu L, Wang G, Lee K et al. Expression of soluble TNFRII from transduced human mesenchymal stem cells: In vitro and in vivo efficacy. Blood 1999;94:400.
56. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cell by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005;52:1595-1603.
57. Augello A, Tasso R, Negrini SM et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007;56:1175-1186.
58. González MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009;60:1006-1019.
59. Mao F, Xu WR, Qian H et al. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflamm Res 2010;59:219-225.
60. Choi JJ, Yoo SA, Park SJ et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008;153:269-276.
61. Schurgers E, Kelchtermans H, Mitera T et al. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010;12:R31-R42.
62. Murphy JM, Dixon K, Beck S et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002; 46:704-713.
63. Wehling N, Palmer GD, Pilapil C et al. Interleukin-1b and tumor necrosis factor a inhibit chondrogenesis by human mesenchymal stem cells through NF-kB-dependent pathways. Arthritis Rheum 2009;60:801-812.
64. Heldens GT, Davidson EN, Vitters EL et al. Catabolic factors and osteoarthritis-conditioned medium inhibit chondrogenesis of human mesenchymal stem cells. Tissue Eng Part A 2012;18:45-54.
65. Johnston J, Tazelaar J, Rivera VM et al. Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. Mol Ther 2003;7:493-497.
66. Partridge KA, Oreffo RO. Gene delivery in bone tissue engineering: Progress and prospects using viral and nonviral strategies. Tissue Eng 2004;10:295-307.
67. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
68. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506.
69. Atoui R, Chiu RCJ. Concise review: Immunomodulatory properties of mesenchymal stem cells in cellular transplantation: Update, controversies, and unknowns. STEM CELLS TRANSLATIONAL MEDICINE 2012;1:200-205.
70. Ponce S, Orive G, Hernandez RM et al. In vivo evaluation of EPO-secreting cells immobilized in different alginate-PLL microcapsules. J Control Release 2006;116:28-34.
71. Yanay O, Barry SC, Flint LY et al. Longterm erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 2003;14:1587-1593.
72. Mosca JD, Chang YN, Williams G. Antigen-presenting particle technology using inac tivated surface-engineered viruses: Induction of immune responses against infectious agents. Retrovirology 2007;4:32-50.
73. Kueng HJ, Leb VM, Haiderer D et al. General strategy for decoration of enveloped viruses with functionally active lipidmodified cytokines. J Virol 2007;81:8666- 8676.
74. Yang Y, Leggat D, Herbert A et al. A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles. J Interferon Cytokine Res 2009;29:9-22.